Sodium-glucose cotransporter 2 inhibitor use: A pharmaco-ergonomic qualification tool

by Sanjay Kalra, A G Unnikrishnan, Manash Baruah, Pallavi Kawatra, Jignesh Ved
Published 2017-01-01

Sodium–glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case report

by Megumi Yasuda, Katsumi Iizuka, Takehiro Kato, Yanyan Liu, Ken Takao, Kenta Nonomura, Masami Mizuno, Daisuke Yabe
Published 2020-05-01

Enhancement of the serum chloride concentration by administration of sodium–glucose cotransporter-2 inhibitor and its mechanisms and clinical significance in type 2 diabetic patien...

by Hajime Kataoka, Yuichi Yoshida
Published 2020-01-01

Failure to confirm a sodium–glucose cotransporter 2 inhibitor‐induced hematopoietic effect in non‐diabetic rats with renal anemia

by Daisuke Yamazaki, Yoshio Konishi, Takashi Morikawa, Hideki Kobara, Tsutomu Masaki, Hirofumhi Hitomi, Kenji Osafune, Daisuke Nakano, Wararat Kittikulsuth, Akira Nishiyama
Published 2020-07-01

Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study

by Ikuro Matsuba, Takehiro Kawata, Kotaro Iemitsu, Taro Asakura, Hikaru Amemiya, Masashi Ishikawa, Syogo Ito, Mizuki Kaneshiro, Akira Kanamori, Akira Kubota, Kazuaki Shinoda, Masahiko Takai, Tetsuo Takuma, Masahiro Takihata, Hiroshi Takeda, Keiji Tanaka, Yoko Matsuzawa, Hideo Machimura, Fuyuki Minagawa, Nobuaki Minami, Atsuko Mokubo, Masaaki Miyakawa, Yasuo Terauchi, Yasushi Tanaka
Published 2020-09-01

Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes

by Kiyohiko Takahashi, Kyu Yong Cho, Akinobu Nakamura, Aika Miya, Arina Miyoshi, Chiho Yamamoto, Hiroshi Nomoto, Hirokatsu Niwa, Kiyohito Takahashi, Naoki Manda, Yoshio Kurihara, Shin Aoki, Yoichi M Ito, Tatsuya Atsumi, Hideaki Miyoshi
Published 2019-03-01

Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, rando...

by Masaya Koshizaka, Ko Ishikawa, Ryoichi Ishibashi, Yoshiro Maezawa, Kenichi Sakamoto, Daigaku Uchida, Susumu Nakamura, Masaya Yamaga, Hidetaka Yokoh, Akina Kobayashi, Shunichiro Onishi, Kazuki Kobayashi, Jun Ogino, Naotake Hashimoto, Hirotake Tokuyama, Fumio Shimada, Emi Ohara, Takahiro Ishikawa, Mayumi Shoji, Shintaro Ide, Kana Ide, Yusuke Baba, Akiko Hattori, Takumi Kitamoto, Takuro Horikoshi, Ryouta Shimofusa, Sho Takahashi, Kengo Nagashima, Yasunori Sato, Minoru Takemoto, L. Kristin Newby, Koutaro Yokote, the PRIME‐V study group
Published 2021-02-01

Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A random...

by Hideka Inoue, Katsutaro Morino, Satoshi Ugi, Sachiko Tanaka‐Mizuno, Keiko Fuse, Itsuko Miyazawa, Keiko Kondo, Daisuke Sato, Natsuko Ohashi, Shogo Ida, Osamu Sekine, Masahiro Yoshimura, Kiyoshi Murata, Katsuyuki Miura, Hisatomi Arima, Hiroshi Maegawa, the SUMS‐ADDIT‐1 Research group
Published 2019-07-01

Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin

by Aika Miya, Akinobu Nakamura, Kyu Yong Cho, Shinichiro Kawata, Hiroshi Nomoto, So Nagai, Hajime Sugawara, Shinji Taneda, Kazuhisa Tsuchida, Kazuno Omori, Hiroki Yokoyama, Jun Takeuchi, Shin Aoki, Yoshio Kurihara, Tatsuya Atsumi, Hideaki Miyoshi
Published 2021-08-01

Review on sodium-glucose cotransporter 2 inhibitor (SGLT2i) in diabetes mellitus and heart failure

by Akshyaya Pradhan, Shweta Vohra, Pravesh Vishwakarma, Rishi Sethi
Published 2019-01-01

Canagliflozin, a sodium–glucose cotransporter 2 inhibitor, normalizes renal susceptibility to type 1 cardiorenal syndrome through reduction of renal oxidative stress in diabetic ra...

by Yukishige Kimura, Atsushi Kuno, Masaya Tanno, Tatsuya Sato, Kouhei Ohno, Satoru Shibata, Kei Nakata, Hirohito Sugawara, Koki Abe, Yusuke Igaki, Toshiyuki Yano, Takayuki Miki, Tetsuji Miura
Published 2019-07-01

Sustained fasting glucose oxidation and postprandial lipid oxidation associated with reduced insulin dose in type 2 diabetes with sodium–glucose cotransporter 2 inhibitor: A random...

by Ken Kanazawa, Hiroshi Uchino, Fumika Shigiyama, Hiroyuki Igarashi, Kayoko Ikehara, Fukumi Yoshikawa, Shuki Usui, Masahiko Miyagi, Hiroshi Yoshino, Yasuyo Ando, Naoki Kumashiro, Takahisa Hirose
Published 2019-07-01

Early detection of euglycemic ketoacidosis during thoracic surgery associated with empagliflozin in a patient with type 2 diabetes: A case report

by Chie Kitahara, Shuhei Morita, Shohei Kishimoto, Shohei Matsuno, Shinsuke Uraki, Ken Takeshima, Yasushi Furukawa, Hidefumi Inaba, Hiroshi Iwakura, Hiroyuki Ariyasu, Hiroto Furuta, Masahiro Nishi, Takashi Akamizu
Published 2021-04-01

Do sodium–glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real‐world study

by Bin Zhao, Juan Shen, Jun Zhao, Hui Pan
Published 2021-08-01

Favorable effect of sodium–glucose cotransporter 2 inhibitor, dapagliflozin, on non‐alcoholic fatty liver disease compared with pioglitazone

by Kyu Yong Cho, Akinobu Nakamura, Kazuno Omori, Takahiro Takase, Aika Miya, Kohei Yamamoto, Hiroshi Nomoto, Hiraku Kameda, Shinji Taneda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi
Published 2021-07-01

Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure

by Nikole J. Byrne, BSc, Nirmal Parajuli, PhD, Jody L. Levasseur, BSc, Jamie Boisvenue, BTech, Donna L. Beker, Grant Masson, BSc, Paul W.M. Fedak, MD, PhD, Subodh Verma, MD, PhD, Jason R.B. Dyck, PhD
Published 2017-08-01

Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial

by Hajime Yamakage, Masashi Tanaka, Takayuki Inoue, Shinji Odori, Toru Kusakabe, Noriko Satoh‐Asahara
Published 2020-05-01

Sodium–glucose cotransporter 2 inhibitors reduce day‐to‐day glucose variability in patients with type 1 diabetes

by Koki Chiba, Hiroshi Nomoto, Akinobu Nakamura, Kyu Yong Cho, Kumiko Yamashita, Yui Shibayama, Aika Miya, Hiraku Kameda, Yoshio Kurihara, Shin Aoki, Tatsuya Atsumi, Hideaki Miyoshi
Published 2021-02-01

Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I–III clinical trials

by Daisuke Yabe, Atsutaka Yasui, Linong Ji, Moon‐Kyu Lee, Ronald Ching Wan Ma, Tien‐Jyun Chang, Tomoo Okamura, Cordula Zeller, Stefan Kaspers, Jisoo Lee, Sven Kohler, Yutaka Seino
Published 2019-03-01

Effects of sodium–glucose cotransporter 2 inhibitors in addition to insulin therapy on cardiovascular risk factors in type 2 diabetes patients: A meta‐analysis of randomized contro...

by Bingshu Wu, Hongzhi Zheng, Jianqiu Gu, Yan Guo, Yixuan Liu, Yingfang Wang, Feng Chen, Aolin Yang, Jiabei Wang, Hailong Wang, Ying Liu, Difei Wang
Published 2019-03-01